| |
Number
|
%
|
|---|
|
Age
|
|
Median
|
54
| |
|
Range
|
30–75
| |
|
Tumor size
|
|
Median
|
30
| |
|
Range
|
13–120
| |
|
T status
|
|
T1
|
8
|
9.6
|
|
T2
|
62
|
74.7
|
|
T3
|
7
|
8.4
|
|
T4
|
6
|
7.2
|
|
N status
|
|
N0
|
40
|
48.2
|
|
N1
|
32
|
38.6
|
|
N2
|
7
|
8.4
|
|
N3
|
4
|
4.8
|
|
Stage before NAC
|
|
Stage II
|
68
|
81.9
|
|
Stage III
|
15
|
18.1
|
|
Type of surgery
|
|
Breast-conserving surgery
|
38
|
45.8
|
|
Mastectomy
|
36
|
43.4
|
|
Skin-sparing mastectomy
|
8
|
9.6
|
|
No operation
|
1
|
1.2
|
|
Type of axial surgery
|
|
Sentinel lymph node biopsy
|
15
|
18.1
|
|
Axial dissection after sentinel lymph node biopsy
|
4
|
4.8
|
|
Axial dissection
|
63
|
75.9
|
|
No operation
|
1
|
1.2
|
|
Subtype
|
|
Luminal A and luminal B
|
54
|
65.1
|
|
Luminal HER2
|
6
|
7.2
|
|
HER2 positive
|
10
|
12.0
|
|
Triple negative
|
13
|
15.7
|
|
Nuclear grade
|
|
I
|
37
|
44.6
|
|
II
|
20
|
24.1
|
|
III
|
20
|
24.1
|
|
Unknown
|
6
|
7.2
|
|
FDG uptake
|
|
Negative
|
0
|
0.0
|
|
Positive
|
83
|
100.0
|
|
Regimens of NAC
|
|
wPAC → FEC
|
39
|
47.0
|
|
DOC → FEC
|
39
|
47.0
|
|
FEC → DOC
|
2
|
2.4
|
|
FEC → DOC + H
|
1
|
1.2
|
|
FEC → PTX + Bev
|
1
|
1.2
|
|
wPAC
|
1
|
1.2
|
-
PAC paclitaxel, FEC 5-FU, epirubicin and cycrophsphamide, DOC docetaxel, H trastuzumab, Bev bevacizumab
